Reclast (Zoledronic Acid) vs Evenity (Romosozumab): Head-to-Head Efficacy for Women With Osteoporosis

Import from "@/components/mdx"

What These Two Drugs Actually Do (and Why the Mechanism Matters for You)

The most important difference between Reclast and Evenity is not the fracture number. It is the mechanism. Reclast works by slowing the cells that break bone down. Evenity does that too, and it also directly stimulates the cells that build new bone. That dual action is why Evenity tends to produce faster, larger gains in bone mineral density (BMD) during its 12-month treatment window.

Reclast: Slowing the Teardown

Zoledronic acid is a third-generation bisphosphonate that binds tightly to hydroxyapatite in bone and is taken up by osteoclasts, the cells responsible for bone resorption. Once inside, it inhibits farnesyl pyrophosphate synthase, a key enzyme in the mevalonate pathway, triggering osteoclast apoptosis. One annual 15-minute IV infusion suppresses bone turnover markers for 12 months or longer, which is a meaningful compliance advantage over daily or weekly oral bisphosphonates.

Because zoledronic acid deposits in bone and releases slowly, its antiresorptive effects persist even if you miss a scheduled infusion by several months. That pharmacokinetic durability is particularly useful during perimenopause and early postmenopause, when estrogen withdrawal accelerates bone resorption by roughly 2-fold compared to premenopausal rates.

Evenity: Building While Protecting

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein secreted by osteocytes that normally acts as a brake on bone formation. Block sclerostin, and osteoblast activity increases. Simultaneously, romosozumab reduces levels of RANKL, which blunts osteoclast-driven resorption. This combined effect is sometimes called a "dual window": you gain bone from increased formation and lose less from reduced resorption. The effect on bone formation markers is most pronounced in the first 6 months of the 12-month course, then tapers even while dosing continues, which is why treatment is capped at 12 monthly injections.

Comparing Fracture Efficacy: What the Trials Actually Show

There is no direct randomized trial comparing zoledronic acid to romosozumab. The numbers below come from separate key trials with different comparators and different patient populations. Treating them as equivalent head-to-head data would be misleading.

HORIZON-PFT: The Evidence Base for Reclast

The HORIZON Key Fracture Trial enrolled 7,765 postmenopausal women aged 65 to 89 with osteoporosis (T-score at or below -2.5 at the femoral neck, or pre-existing vertebral fracture). Participants received either zoledronic acid 5 mg IV annually or placebo for 3 years.

Key results:

• Vertebral fractures: 70% relative risk reduction (3.3% vs 10.9% cumulative incidence at 3 years)
• Hip fractures: 41% relative risk reduction (1.4% vs 2.5%)
• Non-vertebral fractures: 25% relative risk reduction
• BMD gains: Mean 6.7% increase at the lumbar spine and 5.1% at the total hip over 3 years

The trial was conducted in postmenopausal women with established osteoporosis. Data in younger premenopausal women or those in early perimenopause are limited; use in those groups is off-label and requires specialist input.

ARCH: The Evidence Base for Evenity

The ARCH trial enrolled 4,093 postmenopausal women with osteoporosis and at least one prior vertebral fracture, comparing romosozumab 210 mg monthly for 12 months followed by alendronate, versus alendronate alone throughout. The primary comparator was alendronate, not zoledronic acid.

Key results at 24 months (12 months romosozumab then 12 months alendronate vs alendronate throughout):

• New vertebral fractures: 48% relative risk reduction (6.2% vs 11.9%)
• Clinical fractures: 27% relative risk reduction
• Hip fractures: 38% relative risk reduction
• Lumbar spine BMD gain at 12 months: +13.7% with romosozumab vs +5.0% with alendronate
• Total hip BMD gain at 12 months: +6.2% vs +2.5%

The cardiovascular imbalance in ARCH was notable: serious cardiovascular events (MI, stroke) occurred in 2.5% of the romosozumab group vs 1.9% of the alendronate group, which drove the FDA black box warning.

Cross-Trial Comparison: An Honest Summary

| Outcome | Reclast vs Placebo (HORIZON-PFT) | Evenity vs Alendronate (ARCH) | |---|---|---| | Vertebral fracture RRR | 70% | 48% | | Hip fracture RRR | 41% | 38% | | Non-vertebral fracture RRR | 25% | 19% | | Lumbar spine BMD gain (12 mo) | ~5% | ~13.7% | | Comparator | Placebo | Alendronate (active drug) |

The 70% vertebral fracture reduction for Reclast looks larger, but it was measured against placebo. Evenity's 48% reduction was against an active comparator that itself reduces fractures by roughly 50% over 3 years. Adjusting for that context, Evenity's absolute fracture prevention may be comparable or superior in very high-risk women, though no trial has confirmed this directly.

BMD Gains: Speed and Magnitude

Evenity produces faster and larger BMD gains over 12 months than any antiresorptive, including zoledronic acid. At the lumbar spine, romosozumab increases BMD by approximately 13.7% in 12 months, compared to around 5% with zoledronic acid over the same period. For a woman who has already fractured and whose T-score is severely low (below -3.0), that speed of bone accrual may matter clinically, reducing fracture risk sooner.

After the 12-month Evenity course ends, however, BMD gains erode unless you transition to an antiresorptive. The standard sequence is Evenity for 12 months, then zoledronic acid annually. That sequential approach is supported by the FRAME-EXTENSION data and endorsed by the Endocrine Society's 2020 osteoporosis guideline, which explicitly recommends transitioning to antiresorptive therapy after anabolic agents.

Who Is Each Drug Right For?

Your fracture risk category, cardiovascular history, life stage, and preference for injection type all shape which drug belongs in your treatment plan.

Reclast Is Likely the Better Fit If You:

• Have postmenopausal osteoporosis at moderate-to-high fracture risk (FRAX 10-year major fracture risk 20% or higher), without a recent prior fracture
• Have had a cardiovascular event in the past 12 months (Evenity is contraindicated)
• Want a once-yearly treatment rather than monthly injections
• Are being treated for the first time and have not previously used an antiresorptive
• Have a GFR at or above 35 mL/min/1.73m² (below this, zoledronic acid is contraindicated due to nephrotoxicity risk)
• Are in early postmenopause and your physician wants a long-term maintenance strategy

Evenity Is Likely the Better Fit If You:

• Have very high fracture risk: a T-score below -3.0, a recent fracture within the past 12 months, or multiple prior vertebral fractures
• Have not responded adequately to bisphosphonates (worsening BMD or fracture on therapy)
• Can commit to 12 monthly clinic or self-injection visits
• Have no history of MI or stroke within the past year
• Are willing to follow Evenity with a bisphosphonate to consolidate gains

Who Should Use Neither Without Specialist Input:

• Premenopausal women: Both drugs carry risks during reproductive years and are not approved for premenopausal osteoporosis except in specific secondary osteoporosis scenarios (e.g., glucocorticoid-induced, oncology-related)
• Women in perimenopause: BMD loss accelerates in the 2-3 years before the final menstrual period; treatment decisions in this window should involve a menopause specialist and consider whether menopausal hormone therapy might address both bone and symptom goals

Pregnancy, Lactation, and Contraception: A Required Reading Section

Both drugs are contraindicated in pregnancy.

Zoledronic Acid (Reclast): Pregnancy and Lactation

Zoledronic acid is classified as FDA Pregnancy Category D (prior to the 2015 labeling shift; current labeling states it may cause fetal harm). In animal studies, it caused skeletal malformations, increased fetal resorption, and perinatal death. Human data are limited, but bisphosphonates accumulate in bone for years and may be released during subsequent pregnancies, crossing the placenta. If you are of reproductive age and considering zoledronic acid, use effective contraception throughout therapy and for an appropriate interval afterward. Discuss this timeline explicitly with your prescribing physician.

Lactation transfer of zoledronic acid is poorly studied. Given its mechanism and bone accumulation, breastfeeding is not recommended during therapy.

Bisphosphonates as a class are generally avoided in women who may become pregnant within the next several years. If you are premenopausal with osteoporosis and planning pregnancy, an alternative such as denosumab or teriparatide with strict contraception and specialist oversight may be considered, though all have their own reproductive risks.

Romosozumab (Evenity): Pregnancy and Lactation

Romosozumab is contraindicated in pregnancy. Animal reproductive studies showed embryo-fetal toxicity. Sclerostin plays a role in normal bone development, and blocking it during fetal development poses theoretical skeletal risks. Because romosozumab is approved only for postmenopausal women, the clinical scenario of pregnancy during treatment is rare but possible in early menopause transition.

Use reliable contraception if there is any possibility of pregnancy. Lactation data are absent; breastfeeding is not recommended.

Contraception Requirement Summary

| Drug | Pregnancy Risk | Lactation | Contraception Required? | |---|---|---|---| | Zoledronic acid | Fetal harm (animal data; some human signal) | Not recommended | Yes, women of reproductive potential | | Romosozumab | Embryo-fetal toxicity | Not recommended | Yes, postmenopausal transition-age women |

Conditions Specific to Women That Influence This Choice

PCOS and Secondary Bone Loss

Women with polycystic ovary syndrome (PCOS) who have hyperandrogenism and regular cycles generally have preserved or even elevated BMD. However, those with hypothalamic amenorrhea or who use injectable progestins for cycle management may develop low bone mass. In that setting, the primary intervention is addressing the underlying hormonal deficiency, not antiresorptive therapy. Neither Reclast nor Evenity is first-line in this group without additional risk factors.

Premature Ovarian Insufficiency (POI)

Women with POI diagnosed before age 40 lose bone rapidly due to prolonged estrogen deficiency. The Endocrine Society recommends menopausal hormone therapy (MHT) as the primary bone-protective strategy in POI until at least age 50, with bisphosphonates reserved for those who cannot or will not use MHT. If a woman with POI has already sustained a fracture or has a T-score below -2.5 and cannot use MHT, zoledronic acid or romosozumab may be appropriate with specialist guidance.

Glucocorticoid-Induced Osteoporosis

Women who use long-term glucocorticoids (prednisone equivalent 5 mg/day or more for 3 months or longer) are at accelerated fracture risk regardless of menstrual status. Zoledronic acid has a specific indication for glucocorticoid-induced osteoporosis in adults, supported by a dedicated RCT published in NEJM. Romosozumab does not currently carry this indication.

Postmenopausal Women With Prior Breast Cancer

Women who have received aromatase inhibitors (AIs) for breast cancer face rapid bone loss; AI-induced bone loss can reach 2-3% per year at the spine. Zoledronic acid is widely used in this population to prevent AI-associated bone loss, with multiple trials showing fracture reduction. Romosozumab's cardiovascular warning and the already elevated cardiovascular risk in many breast cancer survivors make its use in this group a more complex, individualized decision.

Side Effects and Tolerability: What Women Report Most

Reclast Side Effects

The most common side effect is the acute-phase reaction: flu-like symptoms including fever, myalgia, headache, and bone pain occurring 1-3 days after the infusion. This happens in approximately 32% of women after their first infusion and is substantially less common after subsequent annual infusions. Pre-medicating with acetaminophen and staying well-hydrated reduces severity.

Osteonecrosis of the jaw (ONJ) and atypical femoral fracture (AFF) are rare but real. ONJ risk is approximately 1 in 10,000 to 1 in 100,000 patient-years at osteoporosis doses. AFF risk rises with duration of use; after 5 years of bisphosphonate therapy, the risk climbs to roughly 100 per 100,000 patient-years. For most women, the fracture prevention benefit far outweighs these risks for a 3-5 year course.

Nephrotoxicity is dose- and rate-dependent. The infusion must run over at least 15 minutes, and the drug should be avoided in women with a GFR below 35 mL/min/1.73m².

Evenity Side Effects

Injection-site reactions (pain, redness) are common and generally mild. Arthralgias affect roughly 12% of users.

The black box warning for cardiovascular events is the defining safety concern. The FDA requires the prescribing physician to assess cardiovascular risk before starting romosozumab and contraindicates its use within 12 months of a myocardial infarction or stroke. Women with multiple cardiovascular risk factors (diabetes, hypertension, dyslipidemia, smoking history) may be better served by zoledronic acid.

Hypocalcemia can occur with both drugs; calcium and vitamin D repletion before starting either agent is standard practice and reduces this risk.

Monitoring: What to Expect While on Treatment

On Reclast

• DXA at baseline and 1-2 years after starting therapy
• Bone turnover markers (serum CTX, P1NP) at 3-6 months confirm biological response
• Renal function (serum creatinine) before each annual infusion
• Dental exam before starting; avoid elective invasive dental procedures while on therapy

On Evenity

• DXA at baseline and after the 12-month course
• P1NP and CTX at 3-6 months to confirm anabolic response
• Calcium and vitamin D levels at baseline and periodically
• Cardiovascular risk reassessment before each 6-month prescription renewal
• Plan transition antiresorptive therapy before the 12-month course ends; a gap in coverage allows rapid BMD loss

Can You Switch Between These Two Drugs?

Yes, and the switching direction matters. The evidence most strongly supports going from Evenity to an antiresorptive (zoledronic acid or alendronate), not the reverse. In the ARCH trial, women who completed 12 months of romosozumab and then transitioned to alendronate had significantly better outcomes than those who took alendronate throughout.

Switching from zoledronic acid to romosozumab is used clinically when a woman has suboptimal response to bisphosphonate therapy, defined as fracture on treatment or continued significant BMD loss. The American Association of Clinical Endocrinology (AACE) 2020 osteoporosis guidelines support transitioning to an anabolic agent when antiresorptive therapy is insufficient in very-high-risk patients.

After stopping zoledronic acid, there is typically an antiresorptive carry-over period of 12-18 months during which it is safe to begin romosozumab without a major gap in bone protection. Your physician will measure CTX (a bone resorption marker) to confirm how active bone turnover is before making this switch.

The Evidence Gap: What We Still Do Not Know

Women have been historically under-represented in drug development broadly, but osteoporosis trials are a relative exception. Both HORIZON-PFT and ARCH enrolled exclusively or predominantly postmenopausal women, so the trial populations actually reflect the people most likely to use these drugs. Meaningful gaps remain:

• Premenopausal osteoporosis: Neither drug has RCT data in premenopausal women outside of secondary osteoporosis contexts.
• Perimenopausal women: The window between irregular cycles and the final menstrual period is poorly studied for pharmacologic bone therapy.
• Women of color: HORIZON-PFT enrolled approximately 94% white participants. Fracture risk tools like FRAX may underestimate risk in Black women who tend to have higher BMD but are often undertreated. Romosozumab trial populations had similar limitations.
• Long-term Evenity data: The 12-month treatment cap means long-term safety data beyond the sequential-therapy model are limited.
• Direct comparison trial: No head-to-head RCT of zoledronic acid versus romosozumab exists. The cross-trial comparison above is the best available evidence, and it carries all the limitations of indirect comparison.